New ampholyte biomaterial compounds containing ampholyte moieties are synthesized and integrated into polymeric assemblies to provide hydrophilic polymers exhibiting improved biocompatibility, haemocompatibility, hydrophilicity non-thrombogenicity, anti-bacterial ability, and mechanical strength, as well as suitability as a drug delivery platform.

The present invention relates to novel photoinitiators having hydroxyl groups and/or (meth)acrylate groups. The invention also relates to compositions comprising these photoinitiators as well as their use for photopolymerizing ethylenically unsaturated compounds.

New ampholyte biomaterial compounds containing ampholyte moieties are synthesized and integrated into polymeric assemblies to provide hydrophilic polymers exhibiting improved biocompatibility, haemocompatibility, hydrophilicity non-thrombogenicity, anti-bacterial ability, and mechanical strength, as well as suitability as a drug delivery platform.

A pharmaceutically acceptable salt of an acyclic nucleotide phosphoramidate to treat HPV and related conditions including neoplasia, as well as pharmaceutical compositions, morphic forms and dosage forms thereof.

A pharmaceutically acceptable salt of an acyclic nucleotide phosphoramidate to treat HPV and related conditions including neoplasia, as well as pharmaceutical compositions, morphic forms and dosage forms thereof.

A pharmaceutically acceptable salt of an acyclic nucleotide phosphoramidate to treat HPV and related conditions including neoplasia, as well as pharmaceutical compositions, morphic forms and dosage forms thereof.

A pharmaceutically acceptable salt of an acyclic nucleotide phosphoramidate to treat HPV and related conditions including neoplasia, as well as pharmaceutical compositions, morphic forms and dosage forms thereof.

##STR00001##

A polymer of structure (A) with two end group R.sub.3p, and R.sub.4p, and a polymer chain (R) which has either repeat units of structures (Ip) or (IIp). R.sub.3p, is either a C-1 to C-8 alkyl, a moiety of structure (IIIp), or a moiety of structure (IIIpI). R.sub.3p is a C-1 to C-8 alkyl if the repeat unit is (IIp). R.sub.3p is structure (IIIp) or structure (IIIp1) if the repeat unit has (Ip). R4p is either a terminating moiety such as H, a moiety of structure (IVp), a moiety of structure (IVp1), or a moiety of structure (IVp2). R.sub.3p and R.sub.4p cannot respectively, both simultaneously, be moieties of structure (IIIp) and (IVp), simultaneously be moieties of structure (IIIp) and (IVp1), or simultaneously be moieties of structure (IIIp) and (IVp2). The polymer of structure (A) must contain, one grafting end group moiety selected from structures (IIIp), (IVp), (IVp1) or (IVp2). Composition of this with a solvent are used in DSA processing.

Cannabidiol derivatives and medical use thereof, in particular to compounds represented by general formula (I), or stereoisomers, solvates, metabolites, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of the substituents in general formula (I) are the same as those in the description. ##STR00001##

Cannabidiol derivatives and medical use thereof, in particular to compounds represented by general formula (I), or stereoisomers, solvates, metabolites, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of the substituents in general formula (I) are the same as those in the description. ##STR00001##